Loading
PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.
CIViC holds 4 clinical evidence items and 0 assertions across 5 variants, naming Temsirolimus, IGF1R Monoclonal Antibody, JSI-124 and Teprotumumab and others. IntOGen calls it a driver in 12 cohorts (8 activating, 4 loss-of-function), covering Invasive Breast Carcinoma, Oesophagogastric Adenocarcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Lymphoid Neoplasm, Melanoma and others.
In plain words · PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.
No product in this corpus aims at PTPRD yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PTPRD: RNA tissue enhanced (brain 39 nTPM, parathyroid gland 17 nTPM); no normal tissue stained high; highest cancer staining lymphoma (1 of 12 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Oesophageal cancer, Lymphoma, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Small intestine cancer (small bowel adenocarcinoma) and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P23468; CIViC gene PTPRD; IntOGen PTPRD; Human Protein Atlas PTPRD tissue; Open Targets ENSG00000153707 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Krueger N.X. et al, EMBO J, 1990, "Structural diversity and evolution of human receptor-like protein tyrosine phosphatases". Source.
Sources: HGNC HGNC:9668 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23468 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRD (4 evidence items, 0 assertions, 5 variants; diseases: Ewing Sarcoma, Head And Neck Carcinoma, Ewing Sarcoma Of Bone (GraphQL API, CC0)); IntOGen PTPRD (driver in 12 cohorts (Act 8, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2. Location: Membrane (UniProt). Locus 9p24.1-p23 (HGNC).
RNA: tissue enhanced (brain 39 nTPM, parathyroid gland 17 nTPM), detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Kidney Renal Papillary Cell Carcinoma 6 pTPM.
Medium only: urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PTPRD" OR ABSTRACT:"PTPRD" OR TITLE:"protein tyrosine phosphatase receptor type D" OR ABSTRACT:"protein tyrosine phosphatase receptor type D" OR TITLE:"Receptor-type tyrosine-protein phosphatase delta" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase delta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRD, not a curated reading list.
Shares Small intestine cancer (small bowel adenocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Small intestine cancer (small bowel adenocarcinoma), CIViC, IntOGen, Breast cancer (all types).
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen.
Shares Ewing sarcoma, CIViC, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen, Non-Hodgkin lymphoma (all types).
Shares Ewing sarcoma, CIViC.
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen, Breast cancer (all types).